Opinion|Videos|March 31, 2025
IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection
Experts discuss their approaches to first-line renal cell carcinoma treatment selection, comparing immunotherapy (IO)-IO vs IO-tyrosine kinase inhibitor strategies.
Advertisement
Advertisement
Related to this article
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
Phase 2 ASPEN-06 data showed higher response rates with evorpacept added to trastuzumab, ramucirumab, and paclitaxel in HER2-positive gastric cancer.
In 62 patients with ICI-naive HPV16-Positive HNSCC, 17.7% experienced grade 3 or 4 treatment-related adverse events.
Ethan B. Ludmir, MD, details which cholangiocarcinoma subsets, by tumor location, may benefit most from neoadjuvant radiation before surgery.
Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Daniel C. McFarland, DO, and Yesne Alici, MD, discussed medical aid in dying in cancer care, New York’s safeguards, and the role of psycho-oncology.
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
2
CELMoD-Based Maintenance Deepens Responses After ASCT in Multiple Myeloma
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma
5